A vs AES Stock Comparison

Scores Breakdown

Metric	A	AES
📈 Growth	26/30	12/30
💰 Profitability	17/20	10/20
🏦 Financial Health	15/20	12/20
💵 Valuation	16/20	8/20
⚠️ Risk (lower is better)	5/10	4/10
Overall Score	79/100	48/100

Side-by-Side Summaries

A Analysis	AES Analysis
📈 Growth & Financial Trajectory Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility. 💰 Margins & Cash Flow Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity. 🛡️ Balance Sheet & Liquidity Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure. ⚠️ Key Drivers & Risks Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption. Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.	📈 Growth & Financial Trajectory Over the observed 7 quarters, AES's revenues hovered near $3.0B, ending around $2.42B in 2026 Q2, while net income remained positive overall, indicating resilience despite quarterly volatility. The trend shows modest growth from early 2025 into late 2025, with some weakness in 2026 Q2 driven by lower topline and mix. Overall, earnings resilience persisted through the period. 💰 Margins & Cash Flow Gross margin ranged roughly in the high 20s and low 30s percentage; operating margin varied around the mid-teens in stronger quarters and contracted when costs rose. Net cash from operating activities was typically solid (around $1.0B per quarter), but investing cash flow was consistently negative, leading to fluctuating free cash flow and reliance on financing for liquidity. 🛡️ Balance Sheet & Liquidity Total assets near $50B+, liabilities around $40B, and equity near $9–9.8B. Current ratio hovered below 1 in some quarters, reflecting funded working capital needs. Redeemable interests and temporary equity add complexity; overall balance sheet appears leveraged but with steady cash generation. ⚠️ Key Drivers & Risks Drivers: Regulated utility earnings, renewable integration, stable demand Risks: Commodity/energy price sensitivity, regulatory/policy shifts, interest-rate exposure

A Analysis

AES Analysis

📈 Growth & Financial Trajectory

Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility.

💰 Margins & Cash Flow

Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity.

🛡️ Balance Sheet & Liquidity

Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure.

⚠️ Key Drivers & Risks

Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption.
Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.

📈 Growth & Financial Trajectory

Over the observed 7 quarters, AES's revenues hovered near $3.0B, ending around $2.42B in 2026 Q2, while net income remained positive overall, indicating resilience despite quarterly volatility. The trend shows modest growth from early 2025 into late 2025, with some weakness in 2026 Q2 driven by lower topline and mix. Overall, earnings resilience persisted through the period.

💰 Margins & Cash Flow

Gross margin ranged roughly in the high 20s and low 30s percentage; operating margin varied around the mid-teens in stronger quarters and contracted when costs rose. Net cash from operating activities was typically solid (around $1.0B per quarter), but investing cash flow was consistently negative, leading to fluctuating free cash flow and reliance on financing for liquidity.

🛡️ Balance Sheet & Liquidity

Total assets near $50B+, liabilities around $40B, and equity near $9–9.8B. Current ratio hovered below 1 in some quarters, reflecting funded working capital needs. Redeemable interests and temporary equity add complexity; overall balance sheet appears leveraged but with steady cash generation.

⚠️ Key Drivers & Risks

Drivers: Regulated utility earnings, renewable integration, stable demand
Risks: Commodity/energy price sensitivity, regulatory/policy shifts, interest-rate exposure

Similar Companies

AMAT Score: 79 AME Score: 78 ANET Score: 85 GOOGL Score: 80 TMO Score: 75 WAT Score: 78

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"